This invention provides a method of treating a patient afflicted with a neurodegenerative disorder e.g. Huntington's disease comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination...

This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof.

Die vorliegende Erfindung betrifft eine kristalline Form von Tigecyclin die durch ein Pulver-XRD-Muster mit Peaks bei 68 95 98 121 126 181 202 216 233 und 268 ± 02 Grad zwei-Theta gekennzeichnet ist.

Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+) -N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+) -N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

The subject invention provides rasagiline citramide and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof and a compound of rasagiline citramide or a salt thereof.